Precision matters in critical care recovery. Aquadex delivers predictable, safe fluid removal to help support post-surgery recovery and manage kidney injury risk. Trusted by cardiac surgery and ICU teams, Aquadex is redefining patient care when traditional methods fall short. Discover how Aquadex can transform outcomes. www.nuwellis.com
Nuwellis, Inc.
医疗设备制造业
Eden Prairie，Minnesota 2,980 位关注者
Restoring Fluid Balance. Transforming Care.
关于我们
We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we’ve rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow? System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life’s work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Eden Prairie, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions (Nasdaq: CHFS).
- 网站
-
https://www.nuwellis.com
Nuwellis, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 51-200 人
- 总部
- Eden Prairie，Minnesota
- 类型
- 上市公司
地点
-
主要
获取路线
12988 Valley View Rd
US，Minnesota，Eden Prairie，55344
Nuwellis, Inc.员工
-
Daniel Christiansen
Experienced Quality and Quality Systems Engineer, Mentoring and training, Navy Veteran
-
Paul LaVoie
Sr. Product Manager at Boston Scientific
-
Ryan Marthaler
Senior Director | Product Marketing | Product Management | Medical Device
-
Neil Ayotte
Senior Vice President, General Counsel and Chief Compliance Officer at Nuwellis, Inc.
动态
-
Exciting news from Nuwellis! The Centers for Medicare and Medicaid (CMS) assigned Aquadex ultrafiltration therapy to Ambulatory Payment Classification (APC) 5242. Reimbursement rate for outpatient therapy to increase from $413 to $1,639 per day, effective January 1, 2025. “This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” said Nestor Jaramillo, President and CEO of Nuwellis. Read the full press release: https://lnkd.in/g98ASeX5
-
-
https://lnkd.in/gHbJxVgG #NuwellisNews: A newly published study demonstrates the effectiveness of #Aquadex in reducing 60-day hospital readmission rates for patients with acutely decompensated heart failure (ADHF) who are otherwise resistant to diuretic treatment. The study, titled, “Outcomes of Ultrafiltration in community-based hospitals” sought to evaluate and validate the role of a newly implemented Aquadex #ultrafiltration therapy program in a community hospital setting. Read the full press release for more about this new #ClinicalData. #HeartFailure #Ultrafiltration #MedTech
-
-
#NuwellisNews: Nuwellis and DaVita Inc. extend supply and collaboration agreement pilot phase. Read more: https://lnkd.in/gJHUXMeF #Ultrafiltration #MedTech
-
#NuwellisNews: Nuwellis announces purchase agreement with a 50 hospital network for Aquadex ultrafiltration therapy. Read more: https://lnkd.in/gDA8ajkU This new network-wide agreement signifies a broader commitment to providing advanced ultrafiltration technology for heart failure, critical care, and now pediatric patients. #Ultrafiltration #MedTech
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
ir.nuwellis.com
-
#NuwellisNews: Nuwellis receives USPTO notice of patent allowance for innovative pediatric CRRT technology. Read more here: https://lnkd.in/g5n62ieQ This patent strengthens Nuwellis' IP portfolio and paves the way for the development of novel technology that allows healthcare providers to switch seamlessly between stationary operation and "transport" or "ambulation" mode, enabling unprecedented patient mobility. #Ultrafiltration?#MedTech
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology | Nuwellis, Inc.
ir.nuwellis.com
-
#NuwellisNews: Nuwellis announces launch of ultrafiltration therapy using Aquadex SmartFlow? system at Henry Ford Health. Read more here: https://lnkd.in/g8FYwSRT #HeartFailure?#Cardiology?#Ultrafiltration?#MedTech
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow? System at Henry Ford Health | Nuwellis, Inc.
ir.nuwellis.com
-
Will you be at #AKICRRT in San Diego? Join Nuwellis and our strategic partner SeaStar Medical to learn more about Quelimmune? and the latest innovations in #AKI therapies and #CRRT. Register today: https://lnkd.in/g2Kruna #AKICRRT2024 #SCDPED #NephPeds #MedTech
-
-
That’s a wrap on #THT2024! Thank you to the #HeartFailure leaders who connected with us in Boston, and special thanks to Drs.?Maria Rosa Costanzo,?Sean Pinney,?Mark Hofmeyer, Aroti Hegde and?Deya Alkhatib, MD?for supporting our symposium and late-breaking presentations on #aquapheresis advancements. ? Did you miss us at the conference? Get in touch to learn more about innovative therapies for your patients with fluid overload:?https://lnkd.in/gaSHi-th ? #FluidOverload #MedTech #Ultrafiltration #Cardiology
-
#NuwellisNews: Presented at #THT2024, late-breaking results from two new clinical data analyses from the AVOID-HF trial demonstrate the benefits of #Aquadex in helping to reduce heart failure events and hospitalization at 30 days: https://lnkd.in/gvC6KuiH ? ?? Read the full press release for more about this new #ClinicalData. ? #HeartFailure #Cardiology #Ultrafiltration #MedTech